Fujimura M
Third Department of Internal Medicine, Kanazawa University School of Medicine.
Nihon Rinsho. 1996 Nov;54(11):3029-33.
Since tranilast, the first inhibitor of chemical mediator (ICMR), had been assessed to be as effective as disodium cromogycate in asthma, several orally active ICMRs, which have no antihistamine or bronchodilator effect, have been developed and prescribed for asthma control in Japan. On the other hand, as histamine H1-antagonists (H1-antagonists) have been shown to inhibit mediator release from mast cells in vitro, these drugs are sometimes classified as ICMR. ICMRs are effective in 40% of asthmatics but it takes 6 or more months for these drugs to improve the symptoms clearly. Although H1-antagonists are effective in only about 30% of asthmatics, they have been shown to be more effective on cough of asthma, cough variant asthma and atopic cough. H1-antagonists have been shown to strongly inhibit alcohol-induced asthma which is evoked in 60% of Japanese asthmatics.
自从第一个化学介质抑制剂(ICMR)曲尼司特被评估在哮喘治疗中与色甘酸钠效果相当以来,日本已研发出几种无抗组胺或支气管扩张作用的口服活性ICMR,并用于哮喘控制。另一方面,由于组胺H1拮抗剂(H1拮抗剂)已被证明在体外可抑制肥大细胞释放介质,这些药物有时被归类为ICMR。ICMR对40%的哮喘患者有效,但这些药物需要6个月或更长时间才能明显改善症状。虽然H1拮抗剂仅对约30%的哮喘患者有效,但已证明它们对哮喘咳嗽、咳嗽变异性哮喘和特应性咳嗽更有效。H1拮抗剂已被证明能强烈抑制酒精诱发的哮喘,60%的日本哮喘患者会出现这种情况。